Abstract

Arrhythmogenic cardiomyopathy (ACM) is an inherited heart muscle disorder characterized by myocardial fibrofatty replacement and an increased risk of sudden cardiac death (SCD). Originally described as a right ventricular disease, ACM is increasingly recognized as a biventricular entity. We evaluated pathological, genetic, and clinical associations in a large SCD cohort. We investigated 5205 consecutive cases of SCD referred to a national cardiac pathology center between 1994 and 2018. Hearts and tissue blocks were examined by expert cardiac pathologists. After comprehensive histological evaluation, 202 cases (4%) were diagnosed with ACM. Of these, 15 (7%) were diagnosed antemortem with dilated cardiomyopathy (n=8) or ACM (n=7). Previous symptoms, medical history, circumstances of death, and participation in competitive sport were recorded. Postmortem genetic testing was undertaken in 24 of 202 (12%). Rare genetic variants were classified according to American College of Medical Genetics and Genomics criteria. Of 202 ACM decedents (35.4±13.2 years; 82% male), no previous cardiac symptoms were reported in 157 (78%). Forty-one decedents (41/202; 20%) had been participants in competitive sport. The adjusted odds of dying during physical exertion were higher in men than in women (odds ratio, 4.58; 95% CI, 1.54-13.68; P=0.006) and in competitive athletes in comparison with nonathletes (odds ratio, 16.62; 95% CI, 5.39-51.24; P<0.001). None of the decedents with an antemortem diagnosis of dilated cardiomyopathy fulfilled definite 2010 Task Force criteria. The macroscopic appearance of the heart was normal in 40 of 202 (20%) cases. There was left ventricular histopathologic involvement in 176 of 202 (87%). Isolated right ventricular disease was seen in 13%, isolated left ventricular disease in 17%, and biventricular involvement in 70%. Among whole hearts, the most common areas of fibrofatty infiltration were the left ventricular posterobasal (68%) and anterolateral walls (58%). Postmortem genetic testing yielded pathogenic variants in ACM-related genes in 6 of 24 (25%) decedents. SCD attributable to ACM affects men predominantly, most commonly occurring during exertion in athletic individuals in the absence of previous reported cardiac symptoms. Left ventricular involvement is observed in the vast majority of SCD cases diagnosed with ACM at autopsy. Current Task Force criteria may fail to diagnose biventricular ACM before death.

Highlights

  • Arrhythmogenic cardiomyopathy (ACM) is a genetic heart muscle disorder characterized by myocardial atrophy and fibrofatty replacement of the ventricular myocardium

  • In this large comprehensive autopsy study, we demonstrate that left ventricular involvement is observed in most decedents with arrhythmogenic cardiomyopathy and the left ventricle is exclusively involved in nearly a fifth of cases

  • Described as arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC) [1,2], increased recognition of left ventricular (LV) involvement has recently led to adoption of the term ‘ACM’ [3,4]

Read more

Summary

Introduction

Arrhythmogenic cardiomyopathy (ACM) is a genetic heart muscle disorder characterized by myocardial atrophy and fibrofatty replacement of the ventricular myocardium. Clinical presentation of ACM is heterogeneous, and diagnosis can be challenging [3] This is reflected by the Task Force criteria, which integrate a number of structural, histopathological, electrocardiographic, familial, arrhythmic, and genetic parameters [6]. These criteria are derived from cohorts with predominantly right ventricular involvement (ARVC), can potentially fall short for a significant proportion of those with LV dominant or biventricular disease. Arrhythmogenic cardiomyopathy (ACM) is an inherited heart muscle disorder characterized by myocardial fibro-fatty replacement and an increased risk of sudden cardiac death (SCD). Current Task Force criteria may fail to diagnose biventricular ACM prior to death

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call